Pancreatic Steatosis and Its Relationship to β-Cell Dysfunction in Humans

Racial and Ethnic Variations

Lidia S. Szczepaniak, PhD
Ronald G. Victor, MD
Ruchi Mathur, MD
Michael D. Nelson, PhD
Edward W. Szczepaniak, PhD

Nicole Tyer, MD
Ida Chen, PhD
Roger H. Unger, MD
Richard N. Bergman, PhD
Illdiko Lingvay, MD

OBJECTIVE—To evaluate racial/ethnic differences in pancreatic triglyceride (TG) levels and their relationship to β-cell dysfunction in humans.

RESEARCH DESIGN AND METHODS—We studied black, Hispanic, and white adults who completed three research visits: screening and an oral glucose tolerance test; frequently sampled intravenous glucose tolerance tests for evaluation of β-cell function and insulin resistance; and proton magnetic resonance spectroscopy for evaluation of pancreatic and hepatic TG levels.

RESULTS—Pancreatic TG levels were higher in Hispanics and whites than in blacks (P = 0.006). Hepatic TG levels were highest in Hispanics (P = 0.004). Compensatory insulin secretion and disposition index were higher in blacks (P = 0.003 and P = 0.024, respectively). Insulin sensitivity was comparable between Hispanics and blacks and was lower than in whites (P = 0.005). In blacks, compensatory insulin secretion increased steeply with small increments in pancreatic TG levels (R² = 0.45, slope = 247). In whites, the range of pancreatic TG levels was higher, and the slope was less steep than in blacks (R² = 0.27, slope = 27). In Hispanics, pancreatic TG levels were similar to those of whites, but compensatory insulin secretion was described by a combination of pancreatic and hepatic TG levels and visceral fat mass (R² = 0.32).

CONCLUSIONS—in a multiethnic sample of adults with mild obesity and without diabetes, we found striking ethnic differences in the levels of pancreatic TGs and in the relationship between pancreatic TGs and β-cell dysfunction. Our data implicate pancreatic TG content measured by proton magnetic resonance spectroscopy as a noninvasive novel biomarker for pancreatic β-cell dysfunction, especially in the Hispanic population.

Diet-induced obesity (1) dramatically increases the risk—by >40-fold in certain populations (2)—for type 2 diabetes. A better understanding of the underlying mechanisms by which overnutrition-induced obesity causes diabetes could lead to the discovery of novel preemptive interventions.

One putative mechanism is pancreatic steatosis with β-cell lipotoxicity (3). We define steatosis as high levels of triglyceride (TG) droplets in the cytosol of nonadipose cells and lipotoxicity as organ dysfunction caused by steatosis. It is important to note that cytosolic TG droplets are not toxic themselves but byproducts of their exaggerated metabolism are toxic and cause lipotoxic β-cell dysfunction, at least in animal models. In the Zucker diabetic fatty (ZDF) rat, a standard genetic model of obesity-related diabetes, pancreatic steatosis heralds the transition from insulin resistance with compensated hyperinsulinemia to β-cell failure and frank diabetes. In this model, excess of cytosolic TGs marks excessive levels of ceramide and other toxic metabolites that activate inducible nitric oxide synthase to cause progressive β-cell apoptosis and failure (4–6). A key question is to what extent can this mechanistic hypothesis be translated to common obesity-related diabetes in humans?

Localized proton magnetic resonance spectroscopy (1H MRS) was developed as a noninvasive clinical research tool to conduct translational research testing steatosis and lipotoxicity hypotheses with precise in vivo quantification of cytosolic TGs within parenchymal cells of the human skeletal muscle (7), liver (8), and heart muscle (9,10). This research has implicated skeletal muscle and liver steatosis as a cause of insulin resistance (11,12) and cardiac steatosis as a cause of obesity-related cardiomyopathy (13). More recently, we validated localized 1H MRS as a measure of pancreatic TG levels (14). Insulin-secreting β-cells cannot be differentiated from non-insulin-secreting parenchymal cells of the human pancreas with 1H MRS. However, in the ZDF rat, we documented that the accumulation of TGs in pancreatic tissue as measured by 1H MRS closely parallels the development of β-cell failure both in time course and magnitude (14). We then demonstrated that pancreatic TG content is highly reproducible when healthy human subjects are studied repeatedly and that pancreatic TG level increases with increasing stages of human obesity and glucose intolerance even before the development of type 2 diabetes (14).

The goal of this study was to test whether pancreatic TG constitutes a novel biomarker of early (prediabetic) β-cell dysfunction in human subjects representing the three major race/ethnic groups in the United States. African Americans and Hispanic Americans are known to have higher rates of type 2 diabetes than white Americans, even after adjustment for BMI (15). Moreover, Hispanic Americans are known to have higher rates of hepatic steatosis than other groups (8,12). However, ethnic differences in pancreatic steatosis—and its relationship to β-cell dysfunction—have not been studied previously.

RESEARCH DESIGN AND METHODS

Study population
We studied black, Hispanic, and white individuals 18–65 years of age. We...
Pancreatic steatosis and β-cell dysfunction

excluded individuals with type 2 diabetes to have the opportunity to examine steatosis as a potential cause rather than a consequence of β-cell failure. Additional exclusion criteria were as follows: hypertension or other cardiovascular disease; use of medication known to alter fat metabolism (e.g., steroids, pioglitazone, metformin); weight loss within 6 months before the study; any history of pancreatic or liver disorders; daily consumption of more than two alcoholic beverages; and contraindications to magnetic resonance imaging/spectroscopy (metabolic implants, claustrophobia, pregnancy, body weight <50 kg or >160 kg, or body circumference close to or exceeding the magnet bore size). The study was approved by the institutional review boards at both Cedars-Sinai Medical Center and the University of Texas Southwestern Medical Center. All subjects gave their written, informed consent to participate.

Study design
Subjects completed three research visits as follows: two at the outpatient Clinical Translational Research Center and one at the magnetic resonance imaging center. The first visit included initial screening, anthropomorphic measurements, and an oral glucose tolerance test (OGTT). The second visit included a frequently sampled intravenous glucose tolerance test (FSIVGTT) to assess blood sampling. A bolus of 50% glucose solution (0.3-g glucose/kg body weight) was injected at time 0, and a bolus of regular human insulin (0.03 units/kg body weight) was injected 20 min later. Blood samples were collected for determination of plasma glucose and insulin levels at −15, −10, −5, −1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180 min. Data were analyzed using the Millennium Minimal Model software (18). A compensatory insulin secretion (acute insulin response to glucose [AIRg]) describing first-phase insulin secretion was calculated for the first 10 min after the intravenous glucose bolus. The disposition index (DI), which is the product of AIRg and insulin sensitivity (SI), DI = AIRg × SI, was used to estimate β-cell function adjusted for the prevailing SI.

Abdominal magnetic resonance imaging
The amount of subcutaneous and visceral abdominal fat was determined from a single abdominal axial image at the level between the vertebral L2 and L3 bodies (19). Image analysis was performed by a single observer blinded to the volunteer’s characteristics using Slice-O-Matic software (4.3 rev 10; Virtual Magic Inc., Montreal, Canada).

1H MRS
Pancreatic TGs and hepatic TGs were quantified using 1H MRS at 1.5 Tesla as previously described (8,14). In brief, with the volunteer in the supine position, high-resolution, perpendicular images through the abdomen were collected to locate the pancreas and the liver. Images were acquired with a breath-hold at the end of expiration. The volume for spectroscopic testing was selected with special attention to exclude any visceral fat (Fig. 1). Large volumes of interest (pancreas, 2 mL; liver, 8 mL) were used to obtain mean values of pancreatic and hepatic TGs by 1H MRS. Spectroscopic data (Fig. 1) were collected as volunteers breathed freely, and the 1H MRS signal was triggered at exhalation. Data were acquired and processed using previously described parameters (8,14).

Complete spectroscopic data were obtained on 92 of 100 subjects who were eligible and enrolled. We excluded from analysis pancreatic TG data from five subjects and hepatic TG data from three other subjects because of distortion induced by poorly compensated abdominal motion.

Biochemical analyses
Plasma glucose, plasma TGs, cholesterol, and HDL cholesterol, alanine transaminase, and aspartate transaminase concentrations were determined by enzymatic colorimetric assays using a Chemistry Analyzer Model ATAC 8000 (Elan Diagnostico Co., Brea, CA) (20). LDL cholesterol levels were calculated using the Friedewald equation (21). Plasma insulin was quantified by a paramagnetic particle chemiluminescent immunoassay using the Beckman Immunoassay Systems Access II (Beckman Coulter, Inc., Chaska, MN).

Statistical analysis
Descriptive statistics were used to compare subjects across the three ethnic groups. We tested for group differences using ANOVA for normally distributed variables and Kruskal-Wallis tests for nonnormally distributed variables. The χ2 test was used to test for group differences in distribution of sex. ANCOVA models included sex, age, BMI, and serum TG levels as covariates. We used stepwise linear regression to model AIRg as a function of TGs in visceral, pancreatic, and hepatic compartments; a separate model was developed for each of the three ethnic groups.

Data are presented as mean ± SE unless otherwise stated. Statistical significance was set at the P < 0.05 level. Pearson r was used for bivariate correlation analysis. StatGraphics Centurion XVI software (version 16.1.05; StatPoint Technologies, Inc., Warrenton, VA) was used for the statistical analysis.

RESULTS
Characteristics of the three race/ethnic study groups
We recruited 109 individuals of both sexes. Nine individuals were diagnosed with type 2 diabetes based on the OGTT blood glucose levels and were excluded.
from further studies. The remaining 100 individuals were eligible and enrolled. Race (black or white) and ethnicity (Hispanic or non-Hispanic) were self-identified. The three study groups included 30 non-Hispanic white subjects, 50 Hispanic white subjects, and 20 non-Hispanic black subjects; throughout the article, the groups are referred to as white, Hispanic, and black.

The general characteristics, metabolic variables, and abdominal fat distribution of the three race/ethnic study groups are shown in Table 1. Subjects were relatively young adults (mean age, 39 ± 1 years) with mild obesity (mean BMI, 30 ± 1 kg/m²). The groups were matched on general characteristics such as age, BMI, sex, and blood pressure, as listed in Table 1. Mean values of the metabolic variables also listed in Table 1 were within normal limits by clinical standards. However, fasting and 2-h insulin levels were lower in white subjects than in the other groups; hemoglobin A1c was higher in Hispanics; HDL cholesterol was lower in Hispanics; and alanine transaminase was lower in whites.

Subcutaneous fat mass did not differ among groups (P = 0.871), but visceral fat mass did differ (P < 0.013), being highest in Hispanic subjects (161 ± 12 cm²), lowest in black subjects (98 ± 12 cm²), and intermediate in white subjects (134 ± 8 cm²).

**Pancreatic and hepatic TG levels**
As shown in Fig. 1, pancreatic TG levels were approximately threefold higher in Hispanic subjects and white subjects than in black subjects (P = 0.006, blacks vs. others). In contrast, hepatic TG levels were approximately fivefold higher in Hispanic subjects than in black subjects and approximately threefold higher than in white subjects (P = 0.004, Hispanic vs. others).

Pancreatic TGs did not correlate with serum TGs in any race/ethnic group (r² = 0.03 in black subjects, r² = 0.004 in Hispanic and white subjects). Pancreatic TGs also did not correlate with hepatic TGs in black (r² = 0.03) and Hispanic subjects (r² = 0.11) but showed some correlation in white subjects (r² = 0.28).

**FSIVGTT**
As shown in Fig. 2, compensatory insulin secretion was ~200% higher (P = 0.003) and DI was ~30% higher in black subjects (P = 0.024, blacks vs. others). SI was comparable between Hispanic and black subjects and lower compared with white subjects (P = 0.005, whites vs. others).

To clarify whether the modest differences in glycemic status determined the observed ethnic differences we performed an additional data analysis, which included hemoglobin A1c as an independent covariate. The ethnic differences in our outcomes (including pancreatic and hepatic TG levels, SI, compensatory insulin secretion, and DI) remained significant.

**Relationship between compensatory insulin secretion and pancreatic TG by race/ethnicity**
The relationship between compensatory insulin secretion and pancreatic TG levels varied greatly by race/ethnicity (Fig. 3). In black subjects, compensatory insulin secretion increased steeply with small increments in low levels of pancreatic TGs. In white subjects, the range of pancreatic TG was much higher and the slope of the line relating compensatory insulin secretion to pancreatic TG was much less steep (weaker) than in blacks. In Hispanic subjects, the range of pancreatic TG levels was similar to that in whites, but the relationship between compensatory insulin secretion and pancreatic TG was best described as negative.

**Multivariable modeling**
Stepwise linear regression analysis of compensatory insulin secretion (AIRg) versus three independent variables—pancreatic TGs, hepatic TGs, and visceral fat mass—yielded different equations for each of the three race/ethnic groups.
Pancreatic steatosis and β-cell dysfunction

Changes in pancreatic TGs predicted 30% of the variability in compensatory insulin secretion ($R^2 = 0.30$; adjusted $R^2 = 0.27$). In Hispanic subjects, the model selected three independent variables to predict compensatory insulin secretion: visceral fat mass, pancreatic TGs, and hepatic TGs. The contribution from pancreatic TGs was negative:

$$\text{AIR}_g = 207 + 2 \times \text{visceral fat mass} - 38 \times \text{pancreatic TG} + 17 \times \text{hepatic TG}$$

This model predicted 38% of the variability in compensatory insulin secretion ($R^2 = 0.38$; adjusted $R^2 = 0.32$).

**CONCLUSIONS**—In a multiethnic sample of relatively young men and women with stage I obesity and without diabetes, we found striking ethnic differences in the levels of pancreatic TGs and in the relationship between pancreatic TGs and β-cell dysfunction. Black subjects have very low levels of pancreatic TGs and robust compensatory insulin secretion; small increments in pancreatic TGs are accompanied by large linear increases in a compensatory insulin secretion. White subjects have much higher pancreatic TG levels and a flatter positive relationship between pancreatic TGs and compensatory insulin secretion. Hispanic subjects have levels of pancreatic TGs similar to those of whites but the relationship between pancreatic TGs and insulin secretion is paradoxically negative. The lower level of pancreatic TGs in black compared with Hispanic adults adds to our previous work, showing lower levels of hepatic TGs in black than Hispanic individuals (8), which also was

<table>
<thead>
<tr>
<th>Variable</th>
<th>All</th>
<th>Black</th>
<th>Hispanic</th>
<th>White</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>100</td>
<td>20</td>
<td>50</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>General characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (%)</td>
<td>42</td>
<td>35</td>
<td>48</td>
<td>37</td>
<td>0.4744</td>
</tr>
<tr>
<td>Age (years)</td>
<td>39 ± 1</td>
<td>37 ± 3</td>
<td>37 ± 1</td>
<td>43 ± 2</td>
<td>0.0595</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30 ± 1</td>
<td>32 ± 2</td>
<td>30 ± 1</td>
<td>30 ± 1</td>
<td>0.4075</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>119 ± 1</td>
<td>123 ± 2</td>
<td>119 ± 2</td>
<td>118 ± 3</td>
<td>0.206</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>75 ± 1</td>
<td>76 ± 3</td>
<td>74 ± 2</td>
<td>75 ± 2</td>
<td>0.7458</td>
</tr>
<tr>
<td>Metabolic variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
<td>5.1 ± 0.1</td>
<td>5.3 ± 0.1</td>
<td>5.2 ± 0.1</td>
<td>4.9 ± 0.1</td>
<td>0.0768</td>
</tr>
<tr>
<td>Fasting insulin (pmol/L)</td>
<td>56 ± 7</td>
<td>69 ± 14</td>
<td>56 ± 7</td>
<td>35 ± 7</td>
<td>0.0164</td>
</tr>
<tr>
<td>2-h insulin (pmol/L)</td>
<td>472 ± 42</td>
<td>521 ± 83</td>
<td>556 ± 69</td>
<td>306 ± 42</td>
<td>0.0066</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>117 ± 7</td>
<td>98 ± 8</td>
<td>132 ± 11</td>
<td>104 ± 10</td>
<td>0.1616</td>
</tr>
<tr>
<td>Hemoglobin A₁c (%)</td>
<td>5.6 ± 0</td>
<td>5.6 ± 0</td>
<td>5.8 ± 0</td>
<td>5.3 ± 0</td>
<td>0.0003</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>117 ± 3</td>
<td>191 ± 7</td>
<td>173 ± 5</td>
<td>174 ± 6</td>
<td>0.0659</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>107 ± 3</td>
<td>121 ± 8</td>
<td>103 ± 4</td>
<td>106 ± 5</td>
<td>0.1479</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>45 ± 1</td>
<td>51 ± 4</td>
<td>41 ± 1</td>
<td>47 ± 2</td>
<td>0.0132</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>23 ± 1</td>
<td>24 ± 2</td>
<td>24 ± 1</td>
<td>20 ± 1</td>
<td>0.1233</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>24 ± 2</td>
<td>23 ± 3</td>
<td>27 ± 3</td>
<td>18 ± 2</td>
<td>0.0191</td>
</tr>
<tr>
<td>Visceral fat mass (cm²)</td>
<td>140 ± 8</td>
<td>98 ± 12</td>
<td>161 ± 12</td>
<td>134 ± 15</td>
<td>0.013</td>
</tr>
<tr>
<td>Subcutaneous fat mass (cm²)</td>
<td>254 ± 16</td>
<td>294 ± 48</td>
<td>244 ± 18</td>
<td>243 ± 28</td>
<td>0.871</td>
</tr>
</tbody>
</table>

Data are shown as mean ± SE. ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; SBP, systolic blood pressure.

In black subjects, compensatory insulin secretion was predicted exclusively by pancreatic TGs:

$$\text{AIR}_g = 266 + 247 \times \text{pancreatic TG}$$

Changes in pancreatic TG levels explained 49% of the total variability in compensatory insulin secretion variability ($R^2 = 0.49$; adjusted $R^2 = 0.45$).

In white subjects, compensatory insulin secretion also was predicted exclusively by pancreatic TGs:

$$\text{AIR}_g = 183 + 27 \times \text{pancreatic TG}$$

**Figure 2**—Results of the FSIVGTT. Black subjects have the highest compensatory insulin secretion ($\text{AIR}_g$) (left) and the highest DI (middle) but are least sensitive to insulin (right). Hispanic subjects have compensatory insulin secretion and DI values significantly lower than black subjects despite similar insulin resistance. On average, white subjects have low compensatory insulin secretion and DI values similar to those of Hispanic subjects.
confirmed in this study. Importantly, hepatic TGs cannot be used as a surrogate for pancreatic TGs; pancreatic TG levels were elevated similarly in Hispanic and white subjects, whereas hepatic TG levels were excessively high only in Hispanics. Analysis of our subject-specific data shows that pancreatic TGs cannot be inferred either from hepatic TGs or from serum TGs, thus necessitating direct organ-specific measurement by $^1$H MRS.

It was reported previously that pancreatic TG levels as measured by $^1$H MRS are elevated in patients with type 2 diabetes as well as in those with impaired glucose tolerance, impaired fasting glucose, or both (22–24); however, no relation of pancreatic TGs to $\beta$-cell dysfunction was found for exclusively middle-aged or older white European subjects. The enrichment of our study sample with blacks and Hispanic young adults enhanced our ability to define these relationships. Our spectroscopic data confirm and extend a previous study of an adolescent population that indicated a lower level of pancreatic TGs in black teenagers than in Hispanic teenagers (25). In that report, the race/ethnicity difference in pancreatic TG levels was small because of the use of a less sensitive method of fat imaging and was related to inflammatory markers and free fatty acids but not to $\beta$-cell function. In contrast, we found a striking relationship between pancreatic TG level and compensatory insulin secretion, which differed dramatically by race/ethnicity.

The steep relationship observed between low levels of pancreatic TGs and compensatory insulin secretion in black adults is consistent with glucose-free fatty acid cross-talk, a well-described phenomenon in which free fatty acids stimulate insulin secretion either directly or secondarily by promoting insulin resistance (26–28). The weaker positive relationship seen in white adults and the inverse relationship seen in Hispanic adults is consistent with lipotoxicity offsetting, or even overriding, glucose-free fatty acid cross-talk. The stimulatory effect of free fatty acids on insulin secretion also has been shown to be attenuated in persons who are genetically predisposed to develop type 2 diabetes (26).

A novel finding of our study is that Hispanic subjects were the only group with both pancreatic and hepatic steatosis, the latter being known to 1) attenuate insulin-mediated suppression of gluconeogenesis, elevating fasting plasma glucose and basal insulin secretion; and 2) augment hepatic TG secretion, exposing the pancreas to a higher TG load (29,30). Thus, we speculate that hepatic steatosis begets pancreatic steatosis.

The marked racial/ethnic variation in pancreatic steatosis and its relationship to compensatory insulin secretion suggests a major influence of ancestral genes. Mutations related to ancestral genes previously have been implicated as a risk factor for hepatic steatosis in individuals of Hispanic ancestry and a protective factor in those of African ancestry (31), with the gene products expressed in both hepatocytes and adipocytes. However, the genetic underpinning for racial/ethnic variation in pancreatic steatosis is unknown and will require further exploration.

Our study has several limitations. $^1$H MRS cannot selectively measure TGs in $\beta$-cells; nevertheless, we previously validated whole pancreas TG level as a valid surrogate for $\beta$-cells (32). Because our study is cross-sectional and correlational, the tight associations found between pancreatic steatosis and $\beta$-cell dysfunction are consistent with the lipotoxicity hypothesis but do not prove causal attribution. However, because we excluded patients with type 2 diabetes, the observed pancreatic steatosis constitutes a putative cause rather than the consequence of $\beta$-cell dysfunction. Moreover, our human data are consistent with extensive studies in the ZDF rat showing that excess pancreatic TGs are converted to toxic intermediates that cause $\beta$-cell apoptosis. Because black adults were resistant to pancreatic steatosis, other mechanisms must mediate the high incidence of type 2 diabetes in the black population. We do not know whether the
Pancreatic steatosis and β-cell dysfunction

pancreatic steatosis and associated β-cell dysfunction in white and Hispanic young adults are reversible. However, a prior study (33) of patients with uncomplicated type 2 diabetes showed that β-cell dysfunction can be rescued by intensive caloric restriction, which also caused a detectable reduction in pancreatic steatosis. Because we studied the three major race/ethnic groups in the U.S., our findings cannot be generalized to other ethnic groups without further study.

This study focused on ethnic differences and did not address potential sex differences. On average, the sex distribution within the groups was balanced (P = 0.4744), although the absolute percentage of Hispanic men was higher compared with white and blacks.

Despite these limitations, the data herein implicate pancreatic TG level measured by 1H MRS as a noninvasive novel biomarker for pancreatic β-cell dysfunction, especially in the at-risk Hispanic population. Pancreatic TGs hold exciting promise as intermediate phenotypes in clinical intervention trials for obesity and as biomarkers to identify mildly obese patients who stand to benefit from early preemptive intervention.

Acknowledgments—This work was supported by National Institute of Health Grants R01-DK081524, K23-RR024470, UL-1TR000124, and UL-1RR024982 and by a grant from The Lincy Foundation.

No potential conflicts of interest relevant to this article were reported.

L.S.S. designed the study, researched and analyzed data, and wrote the manuscript. R.G.V. contributed to study design, discussion, and writing manuscript. R.M. performed experiments, contributed to discussion, and reviewed manuscript. M.D.N. reviewed data, contributed to discussion, and edited manuscript. E.W.S. performed experiments, processed magnetic resonance data, and contributed to discussion. N.T. performed experiments. I.C. processed data and contributed to discussion. R.H.U. and R.N.B. contributed to discussion and data interpretation and reviewed and edited the manuscript. I.L. participated in study design, performed experiments, researched and analyzed data, and contributed to writing the manuscript. I.S.S. is a guarantor of this work and, as such, had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the analysis.

References

26. Boden G. Free fatty acids—the link between obesity and insulin resistance. Endocr Pract 2001;7:44–51
27. Koyama K, Chen G, Lee Y, Unger RH. Tissue triglycerides, insulin resistance, and insulin production: implications for...